DrugDashboards

Propofol

Propofol · PROPOFOL 10 mg/mL · Injection, Emulsion · Intravenous · Pfizer Laboratories Div Pfizer Inc

NDC 00069-0234-20 · 20 VIAL in 1 CARTON / 50 mL in 1 VIAL · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$215.94
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$0.089
HCPCS J2704 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$8,713
1,191 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for propofol (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA205576
TE code
AB
Approval date
Sep 16, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Propofol (Injection, Emulsion)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals Private LimitedPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstPROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 3, 2026
Avenacy, LLCPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.PROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsPROPOFOL 10 mg/mLJul 15, 2026Sep 2, 2026
Civica, IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.PROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
NorthStar Rx LLCPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Pfizer Laboratories Div Pfizer IncPROPOFOL 10 mg/mLJul 15, 2026Aug 31, 2026
Anthea Pharma Private LimitedPROPOFOL 10 mg/mLJul 18, 2026Aug 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Propofol — NDC 00069-0234-20," retrieved September 3, 2026, https://drugdashboards.com/drug/00069023420.

Free to cite with attribution — see how the data is put together.